ASC36o

ASC36o is an orally bioavailable peptide agonist of the amylin receptor currently in the discovery stage for the treatment of obesity. Developed by Ascletis Pharma, the drug is designed to mimic the physiological actions of amylin, a peptide hormone co-secreted with insulin that regulates energy balance by promoting satiety and slowing gastric emptying. By utilizing an oral peptide formulation, ASC36o aims to provide a more convenient, non-invasive alternative to injectable amylin analogs or GLP-1 receptor agonists, potentially improving patient compliance and expanding the therapeutic options for weight management.